Short answer
TriSalus Life Sciences, Inc. (TLSI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released for quarter ended June 30, 2026.
TriSalus Life Sciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Full operating metrics and management commentary contained in Exhibit 99.1
- Exhibit 99.1 furnished under Item 2.02, limiting Section 18 Exchange Act liability absent specific incorporation reference
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $11.4M, up 1.7% year over year, signaling modest commercial growth despite expanded sales investment
- Gross margin improved to 86.8% from 83.9%, supported by lower TriNav unit costs
- Operating loss widened to $9.8M from $7.3M as sales and marketing expense rose to $11.4M
- Cash $46.3M after $46.0M gross Q1 equity proceeds, funding commercial expansion and pipeline development
- 2026 revenue guidance maintained at $54M to $57M, representing expected growth of 19% to 26%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TriSalus Life Sciences, Inc. 8-K filings
Get the next TLSI 8-K as it lands
Follow TLSI for push alerts, or ask the research agent what this filing means.